Abstract: A new method of rapidly analyzing plural substances in the presence of biological catalyzers is disclosed. The method is practiced by way of the steps of injecting both pH buffer solution and specimen into a reaction cell, successively adding a plurality of enzymes to induce up-take reaction of dissolved oxygen, causing the plurality of substances to be subjected to selective oxidation in the stepwise manner, obtaining a stepdown curve of dissolved oxygen by automatically recording the oxidative process by means of a dissolved oxygen sensor, qualitatively determining each of the substances with reference to the kind of added enzymes and the order of their addition and quantitatively determining the same with reference to the extent of decrease in dissolved oxygen. Typically, oxidation of the substances is carried out by way of two or three or further more steps.

Abstract: A process for the removal of non-specific turbidities in the carrying out of determinations according to the immuno-assay principle, wherein an inorganic boron compound is added to the sample solution in combination with a buffer system.

Abstract: A quantitative immunoassay for a beta-lactam antibiotic in a sample, which may contain open and closed ring forms of the antibiotic, is disclosed. Closed-ring forms of the antibiotic in the sample are converted to open-ring protein conjugates and detected through immunospecific reaction with antibodies raised against the open-ring protein conjugate form of the beta-lactam antibiotic.

Abstract: The present invention provides a process for the determination of a specifically bindable substance by incubation of a sample solution with at least three receptors R.sub.1, R.sub.2 and R.sub.3, of which R.sub.1 is specifically bindable with R.sub.2 and R.sub.3, as well as with the substance to be determined, R.sub.2 brings about the binding to a solid phase and R.sub.3 carries a labelling, separation of bound labelling from unbound labelling and measurement of the labelling in one of the two phases, wherein, as receptor R.sub.1, a receptor is used which has at least two binding positions which bind specifically with an epitope of the substance to be determined, as R.sub.2 a conjugate of a partner P.sub.1 of a specifically binding pair and of a substance S which corresponds to the substance to be determined or is a derivative thereof and has at least one epitope of the substance to be determined, the partner P.sub.1 thereby either being bound to a solid phase or being immobilized, and as R.sub.

Abstract: Novel adenocarcinoma binding human monoclonal antibody binds preferentially with ADCA antigens and is useful in diagnostic and imaging methods for identifying and locating adenocarcinoma cells, and in therapeutic methods to reduce the reproduction of adenocarcinoma cells. The novel ADCA antigen is useful in methods for diagnosing the presence of adenocarcinoma. The antigen, antibodies, hybridoma, reagents, therapeutic agents and methods of use are aspects of the invention.

Abstract: A specimen containing N. lactamica, N. meningitidis, N. gonorrhoeae or B. catarrhalis is incubated simultaneously with a first substrate for beta-galactosidase and a second substrate for gamma-glutamyl aminopeptidase to form reaction products with one or the other Neisseriae which yields a detectible first or second signal distinct from each other depending upon the presence of the enzyme. Signals may comprise distinct colors which emit either in the absence or presence of diazo dye coupler. A third substrate specific for prolyliminopeptidase in N. gonorrhoeae may be added to form a detectible third signal of the same type. The third substrate may be incubated simultaneously with the first two substrates or later. The absence of all of the first three signals is a positive indication that the specimen contains B. catarrhalis. Also, a diagnostic test kit for performing the above tests with or without lectin or antibody for agglutination based upon specific recognition.

Abstract: A method of confirming the diagnosis of Kawasaki disease in a patient which comprises assaying the patient's body fluid for the presence of elevated levels of a substance specifically bound by an anti-tumor necrosis factor monoclonal antibody.

Abstract: A method is disclosed for the discrimination between intact and damaged cells in a sample, and more particularly, the method uses a vital nucleic acid dye to selectively stain intact versus damaged cells which then may be counted and sorted by flow cytometry means. The method also may be used in conjunction with fluorescently labelled monoclonal antibodies to simultaneously identify cellular antigens.

Abstract: A process for determining the concentration of a component, such as glucose, uric acid or polyamine, in a body fluid, such as urine, blood, blood serum, blood plasma, saliva or gastric juice, includes processing the body fluid with a catalase or an immobilized catalase for decomposing hydrogen peroxide included in the body fluid. When the body fluid is processed with the calalase, an inhibitor which inhibits the reaction between the catalase and the component is added to the body fluid after processing with the catalase. The process also includes processing the body fluid with a strongly basic anion exchange resin. When the concentration of polyamine in the body fluid is measured, the body fluid is processed with an acylpolyamineamido hydrolysis enzyme for converting acetylpolyamine into polyamine in the body fluid. After processing the body fluid by the these operations, hydrogen peroxide produced by the reaction between an oxidase and the component is measured.

Abstract: The present invention relates to diagnostic methods for detecting or evaluating the presence of periodontal diseases, especially gingivitis, in humans or lower animals by measuring the presence of leukocyte esterase. These diagnostic methods comprise measuring the amount of leukocyte esterase present in the oral cavity of the human or lower aniaml being diagnosed.The present invention further relates to diagnostic products useful in vivo for detecting or evaluating the presence of periodontal diseases, especially gingivitis, in humans. These diagnostic products contain at least one agent useful in detecting the presence of leukocyte esterase, and a carrier material. These diagnostic products must be sterile and safe for in vivo contact with the tissue in the oral cavity of the human being diagnosed.Finally, the present invention further relates to diagnostic kits useful for detecting or evaluating the presence of periodontal diseases, especially gingivitis, in humans.

Abstract: Unique marine amoebae capable of digesting algal cell walls and degrading complex hydrocarbons, including plastics, and methods for treating algae and complex hoydrocarbons using the amoebae and partially purified enzymes from the amoebae.

Abstract: The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance with the invention, cells derived from a desired tissue are inoculated and grown on a pre-established stromal support matrix. The stromal support matrix comprises stromal cells, such as fibroblasts actively growing on a three-dimensional matrix. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal matrix provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts found in vivo.

Abstract: A stable reagent and kinetic assay for .alpha.-amylase is provided. The reagent comprises a substrate for the .alpha.-amylase and various enzymes and cofactors necessary to produce NADH as the end-product of a series of four reactions. The substrate, enzymes, and cofactors are provided in sufficient excess that the .alpha.-amylase from the test sample is the rate-limiting factor. The concentration of .alpha.-amylase in a test sample is determined by measuring the rate of increase in absorbance caused by the production of NADH. The use of the novel cofactor fructose-1,6-diphosphate has been found to impart improved stability to the reagent.